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Research Article
TECRL, a new life-threatening inherited arrhythmia
gene associated with overlapping clinical features
of both LQTS and CPVT
Harsha D Devalla1,*,†, Roselle Gélinas2,3,†, Elhadi H Aburawi4,†, Abdelaziz Beqqali5,†, Philippe Goyette2,
Christian Freund1,6, Marie-A Chaix2,3, Rafik Tadros2,3,5, Hui Jiang7,8,9, Antony Le Béchec10, Jantine J
Monshouwer-Kloots1, Tom Zwetsloot1, Georgios Kosmidis1, Frédéric Latour2, Azadeh Alikashani2,
Maaike Hoekstra5, Jurg Schlaepfer11, Christine L Mummery1, Brian Stevenson10, Zoltan Kutalik10,12,
Antoine AF de Vries13,14, Léna Rivard2,3, Arthur AM Wilde15,16, Mario Talajic2,3, Arie O Verkerk5,‡,
Lihadh Al-Gazali4,‡, John D Rioux2,3,**,†,‡, Zahurul A Bhuiyan17,***,‡ & Robert Passier1,18,****,‡
Abstract
Genetic causes of many familial arrhythmia syndromes remain
elusive. In this study, whole-exome sequencing (WES) was
carried out on patients from three different families that
presented with life-threatening arrhythmias and high risk of
sudden cardiac death (SCD). Two French Canadian probands
carried identical homozygous rare variant in TECRL gene
(p.Arg196Gln), which encodes the trans-2,3-enoyl-CoA reductase-
like protein. Both patients had cardiac arrest, stress-induced
atrial and ventricular tachycardia, and QT prolongation on
adrenergic stimulation. A third patient from a consanguineous
Sudanese family diagnosed with catecholaminergic polymorphic
ventricular tachycardia (CPVT) had a homozygous splice site
mutation (c.331+1G>A) in TECRL. Analysis of intracellular calcium
([Ca2+]i) dynamics in human induced pluripotent stem
cell-derived cardiomyocytes (hiPSC-CMs) generated from this
individual (TECRLHom-hiPSCs), his heterozygous but clinically
asymptomatic father (TECRLHet-hiPSCs), and a healthy individual
(CTRL-hiPSCs) from the same Sudanese family, revealed smaller
[Ca2+]i transient amplitudes as well as elevated diastolic [Ca
2+]i
in TECRLHom-hiPSC-CMs compared with CTRL-hiPSC-CMs. The
[Ca2+]i transient also rose markedly slower and contained lower
sarcoplasmic reticulum (SR) calcium stores, evidenced by the
decreased magnitude of caffeine-induced [Ca2+]i transients. In
addition, the decay phase of the [Ca2+]i transient was slower in
TECRLHom-hiPSC-CMs due to decreased SERCA and NCX activities.
Furthermore, TECRLHom-hiPSC-CMs showed prolonged action
potentials (APs) compared with CTRL-hiPSC-CMs. TECRL knock-
down in control human embryonic stem cell-derived CMs
(hESC-CMs) also resulted in significantly longer APs. Moreover,
stimulation by noradrenaline (NA) significantly increased the
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propensity for triggered activity based on delayed afterdepolar-
izations (DADs) in TECRLHom-hiPSC-CMs and treatment with
flecainide, a class Ic antiarrhythmic drug, significantly reduced
the triggered activity in these cells. In summary, we report that
mutations in TECRL are associated with inherited arrhythmias
characterized by clinical features of both LQTS and CPVT.
Patient-specific hiPSC-CMs recapitulated salient features of the
clinical phenotype and provide a platform for drug screening
evidenced by initial identification of flecainide as a potential
therapeutic. These findings have implications for diagnosis and
treatment of inherited cardiac arrhythmias.
Keywords Arrhythmia; CPVT; iPSC; LQTS; SRD5A2L2
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Genetic Disease
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Introduction
Inherited arrhythmogenic diseases (IADs) are one of the prevalent
causes of sudden cardiac death (SCD) in the young (Wilde & Behr,
2013). IADs can be classified into disorders with or without struc-
tural heart defects. The latter include channelopathies such as long
QT syndrome (LQTS) and catecholaminergic polymorphic ventricu-
lar tachycardia (CPVT), caused by mutations in genes encoding ion
channel or calcium-handling proteins that primarily affect the elec-
trical activity of the heart (Schwartz et al, 2013; Wilde & Behr,
2013).
LQTS is most commonly inherited in an autosomal dominant
mode, where mutations in KCNH2, KCNQ1, and SCN5A account for
the majority of cases (Wilde & Behr, 2013). A very rare autosomal
recessive form of LQTS, often accompanied with sensorineural deaf-
ness (Jervell–Lange-Nielsen syndrome), has been linked to muta-
tions in KCNQ1 and KCNE1. At least 12 other genes have been
linked to LQTS. However, 20–30% of LQTS cases remain genetically
elusive. The mechanism of arrhythmia in LQTS mainly involves QT
prolongation with early afterdepolarization-mediated triggered activ-
ity, which can lead to torsades de pointes (TdP) and ventricular
fibrillation.
CPVT is also commonly inherited as an autosomal dominant
disorder due to mutations in the cardiac ryanodine receptor, RYR2
(65% of all cases). Rare autosomal recessive mutations in the
calcium-sequestering protein, CASQ2 (2–5% of all cases), account
for a small fraction of CPVT population (Lahat et al, 2001; Laitinen
et al, 2001; Priori et al, 2001; Postma et al, 2002). Mutations in
TRDN (Roux-Buisson et al, 2012), a calcium release complex
protein, and CALM1 (Nyegaard et al, 2012), a calcium-binding
protein, have also been implicated in CPVT. Interestingly, CALM1,
CALM2, and CALM3 mutations have also been linked to early-onset
LQTS (Crotti et al, 2013; Reed et al, 2015; Chaix et al, 2016), high-
lighting the locus-disease heterogeneity in IADs. Clinically, a normal
electrocardiogram (ECG) at rest and typical arrhythmias, including
bi-directional and polymorphic ventricular tachycardia (VT), in
response to catecholaminergic stress is observed in CPVT. Suscepti-
bility to VT in response to b-adrenergic stimulation is the hallmark
of CPVT, which manifests as exercise-induced syncope and sudden
death (Leenhardt et al, 2012).
Although understanding of genetic loci associated with IADs has
improved remarkably over the last few years, in a number of cases,
the genetic basis of the clinical phenotype has remained elusive
(Schwartz et al, 2013). Genetic testing in LQTS and CPVT has been
broadly adopted as a screening tool for these potentially fatal
diseases. In cases without known disease-causing mutations, identi-
fying family members at risk of SCD can however be challenging.
Therefore, discovering novel Mendelian disease-causing loci
through genetic testing has the potential to improve clinical care
and prevent SCD.
In this study, we identified mutations in trans-2,3-enoyl-CoA
reductase-like (TECRL) gene in three patients with clinical
arrhythmias in whom none of the mutations in the most common
LQTS and CPVT genes had been detected. Two of these patients
were of French Canadian origin but unrelated and were diagnosed
with LQTS at the Cardiovascular Genetics Center of the Montreal
Heart Institute (MHI). They had strikingly similar cardiac electri-
cal phenotypes characterized by normal QT interval on their ECG
at baseline, adrenergic-induced QT prolongation as well as atrial
and ventricular arrhythmias including aborted SCD. Whole-exome
sequencing (WES) of these patients revealed the presence of an
identical homozygous rare variant in exon 6 of TECRL, also anno-
tated SRD5A2L2 (p.Arg196Gln).
A third patient included in this study belongs to a consan-
guineous Arab family of Sudanese origin reported previously
(Bhuiyan et al, 2007). Members of this family were diagnosed with
early-onset and highly malignant form of CPVT and segregation
analysis indicated an autosomal recessive mode of inheritance.
Sequencing of the coding exons and exon–intron boundaries of
RYR2 and CASQ2 and several other cardiac genes such as KCNJ2,
FKBP12.6, SCN5A, KCNH2, KCNQ1, KCNE1, KCNE2, and NCX1 had
not revealed any mutations. Here, we identified a homozygous G>A
point mutation in the splice donor site of intron 3 of TECRL
(TECRLc.331+1G>A) in the affected individuals of this family. To
date, all but two children, who inherited this mutation in the
affected family, died following a cardiac event during physical
activity. To understand the functional consequence of the
TECRLc.331+1G>A mutation and model the disease phenotype
in vitro, we generated human induced pluripotent stem cells
(hiPSCs) (Takahashi et al, 2007) from a 5-year-old symptomatic
patient (referred to as TECRLHom-hiPSCs), his heterozygous (but
clinically asymptomatic) father (TECRLHet-hiPSCs), and a family
member free of the mutation (CTRL-hiPSCs). hiPSCs were differenti-
ated into cardiomyocytes (CMs) and analyzed in vitro. Using the
patient-derived hiPSC-CMs, we showed that the c.331+1G>A
mutation in TECRL leads to skipping of exon 3. TECRLHom-
hiPSC-CMs recapitulated aspects of the disease phenotype in vitro
including increased susceptibility to triggered activity, which could
be alleviated by treatment with flecainide.
Taken together, the clinical, genetic, and experimental results
from this study have identified TECRL as a new gene associated with
life-threatening inherited arrhythmias displaying features of both
LQTS and CPVT.
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Results
Clinical data
This study reports three patients from three different families
presenting clinically with life-threatening arrhythmias and cardiac
arrest followed by successful resuscitation. Two of these patients
were diagnosed with LQTS at the Cardiovascular Genetics Center of
the Montreal Heart Institute following investigation for aborted
cardiac arrest. They had distinctive clinical features of recurrent
exercise- and emotion-induced atrial and ventricular arrhythmias.
The third patient was from a large consanguineous family with two
sub-families and several children affected with adrenergic-related
lethal events and were previously diagnosed with CPVT (Bhuiyan
et al, 2007). Detailed clinical manifestations of these three patients
and additional family members are described below and in the
Appendix.
Patient 1 is a French Canadian female, who presented with
ventricular fibrillation and cardiac arrest during walking at age 22,
without prior history of syncope or documented arrhythmia.
Coronary angiography, transthoracic echocardiography, and inva-
sive electrophysiological (EP) testing, including ventricular prema-
ture stimulation, were normal. The resting ECG showed a normal
QT interval, but isoproterenol infusion resulted in QT prolongation.
During follow-up, the patient presented with recurrent episodes of
exercise- or emotion-induced atrial and ventricular arrhythmias
resulting in multiple shocks from an implantable cardioverter–
defibrillator (ICD). Arrhythmia was refractory to standard beta-
blockers (metoprolol and bisoprolol) but was finally suppressed by
high doses of nadolol. During further follow-up, repeat echocardiog-
raphy remained normal but significant repolarization abnormalities
with QT prolongation (QTc range: 451–494 ms) during follow-up
were occasionally seen on the resting ECG (Fig 1A); the patient was
therefore diagnosed with LQTS. The parents were not known to be
consanguineous but came from the same town. No family member
was available for genetic testing.
Patient 2 is also a French Canadian female. She presented initi-
ally at age 18 with numerous syncopal episodes triggered by
emotional stress, with documentation of non-sustained VT during
exercise stress testing. Despite beta-blocker therapy, she had an
aborted cardiac arrest during emotional stress at the age of 31. At
rest, the QTc was 437 ms with repolarization abnormalities
(Fig 1B). Coronary angiography and cardiac magnetic resonance
imaging were unremarkable. Sustained polymorphic VT was
inducible with one ventricular extrastimulus during isoproterenol
infusion. Epinephrine challenge resulted in a 57 ms paradoxical QT
prolongation with appearance of ventricular bigeminy, suggesting a
low repolarization reserve compatible with LQTS (Fig 1C). During
follow-up, the patient had multiple episodes of adrenergic atrial and
ventricular arrhythmia resulting in numerous ICD shocks. Electro-
physiological mapping showed an extensive low-voltage area along
the interatrial septum and multiple foci of atrial tachycardia (AT)
was ablated. The combination of AT ablation and nadolol signifi-
cantly decreased arrhythmia recurrence in this patient.
Patient 3 (Subject 1V:13 of Fig 1D) is a Sudanese male who
presented with cardiac arrest at age 4 while running. ECG recording
during successful resuscitation showed ventricular fibrillation and
TdP, which was reversed to sinus rhythm following DC shock. ECG
showed a QTc interval of 450 ms (Fig 1E). He had a second attack
while in hospital but was in sinus rhythm between the two attacks
with a normal QRS axis, aQTc interval of 450 ms, and no ST
changes. He later received an ICD and has had no further syncope
or cardiac arrest. However, ICD interrogation occasionally revealed
a fast rhythm around 193 beats/min (cycle length 310 ms) with
polymorphic ventricular ectopy (Fig 1F). The parents of patient 3
are first-degree cousins and seven of 13 children in the family
presented exertion-induced arrhythmias and/or SCD during early
childhood. In five of these children, an arrhythmic episode was
fatal. Two children (IV:9 and IV:13) survived an arrhythmic attack.
Clinical features of the other affected subjects are summarized in
Appendix Table S1. IV:1, IV:2, IV:4, and IV:10 have been described
earlier (Bhuiyan et al, 2007). Clinical details of IV:8, IV:9, and IV:13
are further detailed in the Appendix.
In summary, the clinical phenotype of the affected individuals is
characterized by: (i) adrenergic VTs with high prevalence of cardiac
arrest and SCD, (ii) recurrent AT sometimes triggering ventricular
arrhythmias, and (iii) normal or mildly prolonged QTc at baseline
with paradoxical QT increase during adrenergic stimulation. Taken
together, the patients from all three families presented a similar
severe arrhythmia phenotype with overlapping features of both
LQTS and CPVT.
WES revealed mutations in TECRL in all three patients
To uncover the underlying genetic cause of arrhythmias in these
patients, WES was performed on genomic DNA from patients and
family members when available. Given the low prevalence of IADs,
the fact that LQTS or CPVT can independently be caused by many
different genes, and reasoning that most mutations identified to date
are non-synonymous and familial in nature, we elected to focus our
analyses exclusively on novel non-synonymous variants.
WES revealed an identical homozygous missense mutation in TECRL in
the French Canadian patients
Patient 1 and patient 2 underwent clinical genetic testing and did
not contain mutations in KCNQ1, KCNH2, SCN5A, KCNE1, or
KCNE2, five genes most frequently implicated in LQTS. Overall,
WES identified 57,828 high-quality single nucleotide variants
(SNVs) and in/dels for these two subjects, 231 of which were novel
non-synonymous coding and splice site variants. Given the striking
similarity in disease phenotype, patient 1 and patient 2 were
screened for variants in the same gene, which resulted in the identi-
fication of an identical novel homozygous single base pair (bp)
mutation in TECRL, resulting in an arginine to glutamine substitu-
tion at position 196 (p.Arg196Gln). We developed a genotyping
assay and confirmed independently that the mutation was homozy-
gous in the two patients and absent in 540 European-derived
chromosomes. The p.Arg196Gln substitution is predicted to be
“probably damaging” by PolyPhen-2, deleterious by SIFT, and is
within a site with a high Genomic Evolutionary Rate Profiling
(GERP) score (5.11).
WES revealed a common homozygous splice site mutation in TECRL in
the affected members of the Sudanese family
The pedigree of the Sudanese family (Fig 1D) was compatible with
autosomal recessive inheritance. To reveal the underlying genetic
EMBO Molecular Medicine Vol 8 | No 12 | 2016 ª 2016 The Authors
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cause of SCD, WES was performed on genomic DNA from two chil-
dren, IV:2 and IV:10, who are first-degree cousins (Fig 1D) with
clinical symptoms. Genomic DNA from the parents of IV:2 (III:1 and
III:2; Fig 1D), who are clinically normal, was also included for WES.
On average, this yielded ≥ 81.5 million reads per sample, 87% of
which could be mapped. The mean coverage of the target region
was < 103-fold, with over 93% of target regions covered by ≥ 10
reads. In total 67,000–78,000 SNVs and 4,300–5,400 small in/dels
were identified in each of the individuals, of which 1,401–1,789
were novel non-synonymous coding and splice site variants.
We then prioritized variants according to disease inheritance
pattern in the index patient, his parents, and affected cousin. This
resulted in identification of five SNVs (Appendix Table S2), all
shared by IV:2 and IV:10 as homozygous and III:1 and III:2 as
heterozygous following expected disease inheritance pattern. All
these variants were further tested in the family members by Sanger
sequencing. Of these, a single bp mutation in ANKRD17
(p.Val1368Gly) and a splice site mutation in TECRL (c.331+1G>A)
were found to be homozygous in all children who had presented
with a clinical phenotype (IV:2, IV:4, IV:8, IV:9, IV:10, and IV:13;
Fig 1D) while the parents (III:1, III:2, III:3, and III:4) were found to
be heterozygous in both families. ANKRD17c.4103T>G and
TECRLc.331+1G>A variants were not reported as single nucleotide
polymorphisms (SNPs) in the general population (neither in dbSNP,
1000 Genomes, 6500 NHLBI, ExAC browser nor in our in-house
CoLaus and Vital-IT/SIB databases) and indicated a substitution
deficit and evolutionary conservation (phastCons-46 way score of
0.498 and GERP++ score of 5.32 for ANKRD17; phastCons-46 way
A
B
C
D
E
F
Figure 1. Arrhythmias in three different patients.
A 12-lead ECG of patient 1.
B 12-lead ECG of patient 2.
C ECG of patient 2 during epinephrine test [A, baseline ECG; B, ECG at 17 min and 47 s, at the beginning of epinephrine infusion (0.2 lg/kg of epinephrine); C, ECG after
the end of epinephrine infusion].
D Pedigree of a family diagnosed with arrhythmias; arrow indicates the proband, and solid symbols represent family members affected by arrhythmias who are also
homozygous for mutations identified by exome sequencing. Crossed symbols indicate deceased individuals. Half-filled symbols correspond to individuals
heterozygous for mutations identified by exome sequencing.
E ECG of patient 3 (subject IV:13) showing mild QTc prolongation.
F ICD interrogation of patient 3 (subject IV:13) reveals an episode of VT.
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score of 0.397 and GERP++ score of 5.23 for TECRL). Additionally,
these mutations were not found in any of control DNA samples
obtained from 72 Saudi Arabian individuals. Importantly, no
ANKRD17 variant was identified in the two French Canadian
patients.
Taken together, the results from the French Canadian and Suda-
nese patients suggested that mutations in TECRL are the most likely
cause of their life-threatening arrhythmia.
TECRL is an endoplasmic reticulum (ER) protein expressed
preferentially in the heart
Human TECRL maps to chromosome 4q13 and contains 12 exons
(Appendix Fig S1A). The open reading frame of TECRL encodes a
363 amino acid protein and predicted to contain a ubiquitin-like
domain in the N-terminal half of the protein, three transmembrane
segments as well as a 3-oxo-5-alpha steroid 4-dehydrogenase
domain in the C-terminal half of the protein (Appendix Fig S1B and
C). The homozygous mutation in TECRL found in patients 1 and 2
(p.Arg196Gln), is located in 6th exon of TECRL, and causes an
amino acid substitution immediately upstream of the 3-oxo-5-
alphasteroid 4-dehydrogenase domain (Appendix Fig S1C). On the
other hand, TECRLc.331+1G>A mutation found in patient 3 is
located in the splice donor site of intron 3 resulting in an internal
deletion in the putative ubiquitin-like domain (Appendix Fig S1A–C).
Comparison of amino acid sequences of TECRL revealed a high
degree of cross-species conservation (Appendix Fig S1D), suggesting
that TECRL might have an essential function in the heart.
Previously, TECRL was identified in a genome-wide transcrip-
tional profiling study of human embryonic stem cells (hESCs) dif-
ferentiating to CMs in vitro. Moreover, in the mouse embryo, its
expression was restricted to the heart and inflow tract (Beqqali et al,
2006). To further define the spatiotemporal expression pattern of
Tecrl during embryonic development, its expression in early mouse
embryos was investigated by in situ hybridization. Tecrl was not
expressed in the cardiac crescent at embryonic day E7.5 (Fig 2A)
but was observed at E8.5 in the entire heart with the strongest
expression occurring in the developing inflow tract (Fig 2B), espe-
cially in the left horn (Fig 2C). At E9.5, Tecrl expression was still
detectable in the atria and ventricles, albeit at lower levels
whereas strong expression remained in the inflow tract (Fig 2D).
From E10 onwards, Tecrl was also expressed at low levels in
somites, particularly in the myotome region, that gives rise to
skeletal muscle (Fig 2E–F). At E10.5, cardiac expression of Tecrl
was no longer restricted to the inflow tract and its expression was
maintained in the somites (Fig 2G). At E14.5, Tecrl was expressed
in the entire myocardium but not in the lungs, which served as
negative control (Fig 2H). In adult mice, reverse transcription
quantitative polymerase chain reaction (RT–qPCR) analyses
showed that Tecrl expression was highest in the heart with very
low to almost undetectable levels in brain, skeletal muscle,
stomach, pancreas, liver, kidney, small intestine, and uterus
(Appendix Fig S1E).
Next, we investigated the distribution of TECRL in human
tissues. Interestingly, TECRL has important sequence identity with
TECR, a gene that encodes a multi-pass membrane protein that
resides in the ER, and belongs to the steroid 5-alpha reductase
family (Moon & Horton, 2003). Expression analysis of TECR and
TECRL across a panel of human tissues clearly demonstrates that
while TECR is ubiquitously expressed, TECRL is predominantly
expressed in the heart and skeletal muscle (Fig 2I). Immunofluores-
cence analysis demonstrated that in COS-1 cells, MYC epitope-
tagged mouse Tecrl protein primarily resides in the ER (Fig 2J),
which was also confirmed in H10 cells by co-localization with
calnexin, an ER chaperone (Fig 2K–M).
Collectively, these results demonstrated that Tecrl encodes an ER
protein expressed preferentially in the heart and that it is evolution-
arily conserved, suggesting an important role in the heart.
Derivation of patient-specific hiPSCs and differentiation to CMs
Skin biopsies were obtained from patient IV:13 carrying the
homozygous TECRLc.331+1G>A mutation, his heterozygous father,
III:3, and a family member, IV:7 who does not carry the mutation.
Dermal fibroblasts (Fig 3A; left image) were reprogrammed to
hiPSCs with Sendai virus vectors encoding the four transcription
factors OCT4, SOX2, KLF4, and MYC. Colonies obtained after repro-
gramming (Fig 3A; center image) morphologically resembled hESC
colonies. hiPSC clones expressed the pluripotency markers, NANOG
and SSEA4 (Fig 3A; right image; Appendix Fig S2), and had a
normal karyotype (Fig 3B; left image; Appendix Fig S2). One line
per genotype was selected for further experiments. The transcrip-
tional profile of the hiPSC lines used in the study was analyzed by
PluriTest (Mu¨ller et al, 2011), which showed a high pluripotency
score and low novelty score as expected (Fig 3B; right image). The
pluripotent nature of the hiPSCs was further confirmed by their abil-
ity to differentiate to derivatives of all three germ layers (Fig 3C).
Importantly, nucleotide sequence analysis confirmed the presence
of a homozygous c.331+1G>A mutation in TECRLHom-hiPSCs
(Fig 3D).
A mutation at the exon 3-intron 3 boundary of TECRL leads to
exon 3 skipping
hiPSCs were differentiated to the cardiac lineage with a monolayer
protocol (Fig 3E), and all three lines produced similar percentages
of CMs. Contractile areas were observed in culture at day 10 of dif-
ferentiation. The structure and organization of sarcomeres in
TECRLHom-hiPSC-CMs, TECRLHet-hiPSC-CMs and CTRL-hiPSC-CMs
was similar based on ACTN2 immunostaining (Fig 3F).
To determine the effect of the c.331+1G>A mutation in TECRL,
cDNA was prepared from hiPSC-CMs and PCR analysis was
performed with primers designed to target TECRL exons 2–4. A
171-bp product is expected if the mRNA of TECRL contains exon 3,
whereas a 126-bp product should be present when exon 3 is miss-
ing. Analysis of the amplicons from TECRLHet-hiPSC-CMs clearly
showed two transcripts, a longer product containing exon 3 and a
shorter DNA fragment lacking exon 3 (Fig 3G; left image). As
expected, CTRL-hiPSC-CMs exclusively yielded the longer PCR
product corresponding to 171 bp. On the contrary, PCR analysis of
TECRLHom-hiPSC-CMs revealed a single product of 126 bp (Fig 3G;
left image), indicating that the c.331+1G>A mutation in the splice
donor site of TECRL intron 3 causes complete skipping of exon 3.
Amplification of the entire TECRL coding region showed a shorter
PCR product (1,046 bp) of TECRL from TECRLHom-hiPSC-CMs
compared to the 1,091-bp amplicon of CTRL-hiPSC-CMs (Fig 3G;
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Figure 2. Spatiotemporal, tissue, and sub-cellular expression analysis of TECRL.
A–H Expression of Tecrl in mouse development. Expression is not observed in (A) the cardiac crescent at E7.5 but is prominent in (B) the inflow tract (ift) region at E8.5,
particularly in (C) the left sinus venosus (lsv). (D) At E9.5, Tecrl expression is observed in all four chambers of the heart but is strongest in the inflow tract. (E–G)
From E10 onwards, Tecrl is expressed in the somites. (H) At E14.5, Tecrl expression is present in the entire myocardium. Atrium (a), ventricle (v), myotome (m),
neural tube (nt), lung (lu), right atrium (ra), left atrium (la), right ventricle (rv), and left ventricle (lv).
I mRNA expression analyses of TECR and TECRL by RT–qPCR in human tissues demonstrate preferential expression of Tecrl in the heart. Bone marrow (Bone M.),
heart, skeletal muscle (Sk.Muscle), uterus, liver, spleen, thymus, thyroid, prostate, brain, lung, small intestine (Small I.), and colon.
J Localization of MYC-Tecrl in COS-1 cells. The accumulation of MYC-Tecrl is perinuclear, consistent with it being localized to the ER. Scale bar: 10 lm.
K–M Co-localization of MYC-Tecrl and the ER marker calnexin in H10 cells. Nuclei stained with DAPI. Scale bar: 10 lm.
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right image). Nucleotide sequencing analysis of the PCR product
from TECRLHom-hiPSC-CMs confirmed deletion of 45 bp correspond-
ing to exon 3.
TECRLHom-hiPSC-CMs exhibit abnormalities in calcium handling
Impaired calcium homeostasis underlies the pathophysiology of
various IADs, particularly CPVT. To investigate whether the
TECRLc.331+1G>A mutation has an effect on canonical calcium-
handling proteins, we investigated their expression at the protein
level by Western blotting. There was a 52% reduction in RYR2
protein and 85% reduction in CASQ2 protein in TECRLHom-hiPSC-
CMs, while SERCA2a, PLB, NCX, and Cav1.2 protein levels were
unaffected (Appendix Fig S3).
Next, we studied intracellular calcium ([Ca2+]i) transients of
TECRLHom-hiPSC-CMs. Fig 4A shows typical [Ca
2+]i transient
recordings of CTRL-hiPSC-CMs, TECRLHet-hiPSC-CMs, and
TECRLHom-hiPSC-CMs following 1-Hz electrical stimulation. A
summary of average [Ca2+]i characteristics is shown in Fig 4B and
C. The [Ca2+]i transient rose markedly slower in TECRLHom-hiPSC-
CMs than in CTRL-hiPSC-CMs (Fig 4A) resulting in a significant dif-
ference in the time required to reach 50% of the [Ca2+]i transient
amplitude, t1/2 (Fig 4B). While there were no significant differences
in systolic [Ca2+]i, the diastolic [Ca
2+]i was markedly higher in
TECRLHom-hiPSC-CMs compared with CTRL-hiPSC-CMs (Fig 4B).
Consequently, the amplitude of the [Ca2+]i transient was lower in
TECRLHom-hiPSC-CMs (Fig 4C). Furthermore, the decay of the
[Ca2+]i transient was remarkably slower in TECRLHom-hiPSC-CMs,
as indicated by the significant increase in the time constant (tau) of
decay (Fig 4C).
To gain further insight into the observed differences in [Ca2+]i
transient properties of TECRLHom-hiPSC-CMs and ascertain the
cause of slower decay time, we measured the activity of sarcoplas-
mic reticulum (SR) Ca2+ ATPase (SERCA), Na+-Ca2+ exchanger
(NCX), and the slow mechanisms (mitochondrial Ca2+ uniporter
and sarcolemmal Ca2+ ATPase) in Ca2+ extrusion from the cyto-
plasm by application of the RYR2 agonist, caffeine, and the NCX1
blocker, NiCl2 (Bassani & Bers, 1995; Dı´az et al, 2004). About
10 mM caffeine induced fast release of Ca2+ from the SR into the
cytosol and SERCA activity (KSERCA) was analyzed by comparing the
rates of decay of spontaneous [Ca2+]i transients (Ksys) and caffeine-
evoked transients (Kcaff). The role of NCX in Ca
2+ removal from the
cytoplasm was obtained through subtraction of the rate of decay
of the caffeine-evoked [Ca2+]i transients (Kcaff) from that of caf-
feine-evoked [Ca2+]i transients in the presence of 10 mM NiCl2
(KCaff+Ni). Representative [Ca
2+]i transients of a CTRL-hiPSC-CM
and TECRLHom-hiPSC-CM are shown in Fig 5A.
The amplitude of caffeine-evoked [Ca2+]i transients in the pres-
ence of NiCl2 was considerably lower in TECRLHom-hiPSC-CMs
compared with CTRL-hiPSC-CMs (Fig 5B). However, fractional
Ca2+ release, which is a measure of the amplitude of the normal
systolic [Ca2+]i transient as a fraction of the amplitude of caffeine-
evoked [Ca2+]i transient in the presence of NiCl2, did not differ
significantly between the groups (Fig 5B). KSERCA and KNCX were
significantly lower in TECRLHom-hiPSC-CMs compared with CTRL-
hiPSC-CMs (Fig 5C). Kslow mechanisms indicated by the rate of Ca
2+
transient decay in the presence of caffeine, and NiCl2 (KCaff+Ni) was
not affected in TECRLHom-hiPSC-CMs (Fig 5C).
Although SERCA and NCX activities were lower in
TECRLHom-hiPSC-CMs, the relative contribution of SERCA, NCX,
and slow mechanisms to [Ca2+]i transient decay did not differ
significantly between the groups (Fig 5D). SERCA and NCX
removed 65–70% and 25–30% of the activator Ca2+ from the
cytosol, respectively, whereas the mitochondrial Ca2+ uptake
and sarcolemmal Ca2+-ATPase accounted for the removal of
< 8% of [Ca2+]i.
The [Ca2+]i transient properties of TECRLHet-hiPSC-CMs were
largely in between CTRL-hiPSC-CMs and TECRLHom-hiPSC-CMs,
suggesting a gene dosage dependency (Figs 4B and C, and 5B–D).
TECRLHom-hiPSC-CMs and hESC-CMs with TECRL knockdown
exhibit prolonged APs
Increased diastolic [Ca2+]i is believed to be a substrate for delayed
afterdepolarizations (DADs) leading to triggered arrhythmias which
maybe further aggravated by catecholaminergic stimulation.
TECRLHom-hiPSC-CMs showed elevated diastolic [Ca
2+]i which
prompted us to investigate their action potential (AP) properties.
We also studied the AP parameters of hESC-CMs with TECRL knock-
down in order to compare their electrophysiological phenotype to
TECRLHom-hiPSC-CMs.
First, we studied the AP properties of TECRLHom-hiPSC-CMs
(Fig 6A). Representative APs and averaged AP parameters of hiPSC-
CMs from CTRL, TECRLHet, and TECRLHom lines paced at 1-Hz are
shown in Fig 6B and C. Average resting membrane potential (RMP),
maximum upstroke velocity (dV/dtmax), maximal AP amplitude
(APAmax), and AP plateau amplitude (APAplat) did not differ signifi-
cantly between the three groups (Fig 6C). However, APs of
TECRLHom-hiPSC-CMs displayed marked prolongation of AP dura-
tion (APD) at 20% repolarization (APD20) and there was a clear
Figure 3. Generation of hiPSCs and differentiation to cardiomyocytes.
A Skin fibroblasts (left) from IV:13, homozygous for the TECRLc.331+1G>A mutation, were reprogrammed to hiPSCs (center), which expressed the pluripotency markers
NANOG and SSEA4 (right). Scale bars: 100 lm.
B TECRLHom-hiPSCs have a normal karyotype (left) and PluriTest demonstrates a high pluripotency score and low novelty score for all three hiPSC lines (right).
C TECRLHom-hiPSCs generate derivatives of mesoderm (left), endoderm (center), and ectoderm (right). Scale bars: 25 lm.
D DNA sequencing confirms TECRLc.331+1G>A in the affected family members. Control (left); heterozygous (center); homozygous (right).
E Schematic of the protocol used for cardiac differentiation of hiPSCs.
F ACTN2 immunostaining of CTRL-, TECRLHet-, and TECRLHom-hiPSC-CMs. Scale bar: 25 lm.
G Analysis of RT–PCR products by gel electrophoresis. Amplification products of TECRL exons 2–4 from CTRL-, TECRLHet-, and TECRLHom-hiPSC-CMs (left) and coding
sequence of TECRL from CTRL- and TECRLHom-hiPSC-CMs (right).
Source data are available online for this figure.
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trend for an increase in APD at 50% (APD50) and 90% (APD90)
repolarization compared to CTRL-hiPSC-CMs (Fig 6C).
Next, we performed lentiviral short hairpin (sh) RNA-mediated
knockdown of TECRL in hESC-CMs to study their AP properties.
Lentiviral vectors encoding five different TECRL-specific shRNAs
(Appendix Table S3) for TECRL were tested in hESC-CMs, two of
which (TECRL-sh#3 and TECRL-sh#4) gave efficient knockdown as
assessed by RT–qPCR. Primer sequences are provided in Appendix
Table S4. However, following puromycin selection, hESC-CMs
treated with TECRL-sh#4 showed pronounced cytotoxicity
(Appendix Fig S4A). Therefore, TECRL-sh#3 (hereinafter referred to
as shTECRL) was selected for further experiments and transduction
in hESC-CMs resulted in 70% reduction in TECRL mRNA level in
comparison with cells exposed to a control vector (shCONTR;
Appendix Fig S4B). hESC-CMs transduced with shCONTR or
shTECRL maintained their cardiac phenotype and knockdown of
TECRL in hESC-CMs did not affect TNNT2 expression
(Appendix Fig S4B). AP parameters of shCONTR- or shTECRL-
A
B
C
Figure 4. Whole-cell [Ca2+]i transients in hiPSC-CMs.
A Representative traces of [Ca2+]i transients in Indo-1 AM-loaded hiPSC-CMs paced at 1 Hz.
B Time to reach 50% of [Ca2+]i transient amplitude (t1/2) and [Ca
2+]i concentrations during systole and diastole.
C Amplitude and tau decay of the [Ca2+]i transient.
Data information: n = 5–6 cells each from three independent experiments (mean  SEM); *P < 0.05, statistical significance was assessed with one-way ANOVA on ranks
followed by Dunn’s test in case of failed normality or variance. Otherwise, one-way ANOVA followed by Student–Newman–Keuls test was used.
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transduced hESC-CMs stimulated at 1-Hz were recorded, and repre-
sentative traces as well as averaged data are shown in Appendix Fig
S4C and D. RMP, dV/dtmax, APAmax, and APAplat did not differ
significantly between the two experimental groups (Appendix Fig
S4D). However, hESC-CMs treated with shTECRL displayed signifi-
cantly prolonged APs as evidenced by the increase in APD20, APD50,
and APD90 values (Appendix Fig S4D). In addition, Western blotting
for canonical calcium-handling proteins revealed a 56% decrease in
RYR2 protein and 18% decrease in CASQ2 in shTECRL-treated
hESC-CMs while SERCA2a, PLB, NCX1, and Cav1.2 protein levels
were unaffected (Appendix Fig S4E).
TECRLHom-hiPSC-CMs have an increased susceptibility to
triggered activity
To evaluate the susceptibility of TECRLHom-hiPSC-CMs to triggered
activity, we applied a fast pacing episode (3 Hz; 10 s), followed by
a 10-s pause in the absence or presence of 10 nM noradrenaline
(NA). Representative traces of CTRL-hiPSC-CMs and TECRLHom-
hiPSC-CMs, in the absence and presence of NA, are shown in Fig 7A
and C, respectively. In the absence of NA, the last stimulated AP
(arrow) is followed by APs which seem to be due to diastolic depo-
larization rather than DADs (Fig 7A) since the frequency of such
“triggered” APs did not differ significantly between the experimental
groups (Fig 7B). Moreover, the prevalence of “triggered” and spon-
taneous APs (i.e., APs elicited without a fast pacing protocol) was
also found to be similar in the absence of NA (Fig 7B), which
further suggests that the “triggered” APs in Fig 7A are not due to
DADs. However, in the presence of NA, “triggered” APs were abun-
dantly present in TECRLHom-hiPSC-CMs compared with CTRL-
hiPSC-CMs (Fig 7C). The incidence of “triggered” APs was also
significantly higher than that of spontaneous APs (Fig 7D), indicat-
ing that the higher frequency of “triggered” APs in TECRLHom-
hiPSC-CMs is due to DADs rather than spontaneous activity. Similar
to what was observed for [Ca2+]i transient properties, AP properties
and susceptibility to triggered activity of TECRLHet-hiPSC-CMs were
largely in between those of CTRL-hiPSC-CMs and TECRLHom-hiPSC-
CMs.
Effect of flecainide on hiPSC-CMs
Flecainide, a class Ic antiarrhythmic drug, has been shown to be
effective in CPVT patients, (Watanabe et al, 2009; van der Werf
et al, 2011) although its precise mechanism of action has been a
point of debate. To investigate whether flecainide has an effect on
triggered activity of TECRLHom-hiPSC-CMs, we administered 5 lM
of the drug and analyzed AP properties.
Figure 8A shows typical APs of a TECRLHom-hiPSC-CM in the
absence and presence of flecainide. The average effects of flecainide
on AP parameters in all three hiPSC-CM groups are summarized in
Fig 8B. Flecainide reduced the dV/dtmax and caused AP prolonga-
tion in all three groups without affecting the RMP (Fig 8B). These
effects did not differ significantly between the groups. Figure 8C
shows typical examples of triggered (top) and spontaneous (bottom)
APs of a TECRLHom-hiPSC-CM in the absence and presence of fle-
cainide. The averaged effects of the drug on triggered and sponta-
neous activity in the three experimental groups are summarized in
Fig 8D. While flecainide reduced the frequency of both triggered
and spontaneous activity (Fig 8D), these reductions were not signifi-
cantly different between the three groups. However, the reduction
in triggered activity was more pronounced than that of spontaneous
activity in TECRLHet-hiPSC-CMs and TECRLHom-hiPSC-CMs
(Fig 8D). These results suggest that a treatment regimen with fle-
cainide might be effective in preventing arrhythmias in patients
carrying the TECRLc.331+1G>A mutation.
Discussion
The etiology of a number of IADs remains unknown, and similar
diagnostic challenges are seen in other cardiac diseases. For exam-
ple, LQTS is a condition with monogenic inheritance for which
hundreds of rare mutations have been reported in 16 genes (LQTS1-
16). LQTS patients are grouped into distinct syndromes based on
their clinical characteristics as well as their genotypes. However,
30% of patients are without a genetically confirmed diagnosis and
remain at risk of cardiac events and sudden death (Tester & Acker-
man, 2006). Similarly, in CPVT, 35–45% of the patients without a
known genetic cause remain at risk for adverse arrhythmic events
(Ackerman et al, 2011). WES has emerged as a means to meet this
challenge (Biesecker & Green, 2014). In the current study, we used
WES to identify TECRL as a novel life-threatening inherited arrhyth-
mia gene associated with a recessive form of inherited arrhythmia
with a clinical phenotype that has overlapping features of LQTS and
CPVT.
Clinically, affected individuals from the Sudanese family and
both French Canadian cases presented with stress-induced ventricu-
lar arrhythmias including SCD or aborted SCD. At rest, the QTc was
normal or mildly prolonged while pharmacological sympathetic
stimulation resulted in paradoxical QT prolongation as demon-
strated in the French Canadian cases. Notably, affected individuals
in the Sudanese family presented arrhythmias in childhood while
the onset of symptoms in both French Canadian patients was in
early adulthood. The most likely explanation for this difference in
the age of onset is the more drastic effect of the splice site mutation
identified in the Sudanese family. In all cases, the disease is highly
penetrant and life-threatening, with all affected individuals having
experienced cardiac arrest at a young age. The French Canadian
Figure 5. [Ca2+]i extrusion mechanisms in hiPSC-CMs.
A Representative traces of [Ca2+]i transients in Indo-1 AM-loaded hiPSC-CMs paced at 1 Hz, in the presence of caffeine (caff) or caffeine and NiCl2.
B Amplitude of [Ca2+]i in the presence of caffeine and NiCl2 and fractional SR release in hiPSC-CMs.
C Rate constants of SERCA-, NCX-, and slow mechanism-based [Ca2+]i decay in hiPSC-CMs.
D Relative contribution of SERCA, NCX, and slow mechanisms to [Ca2+]i extrusion in hiPSC-CMs.
Data information: n = 2–3 cells each from three independent experiments (mean  SEM); *P < 0.05, statistical significance was assessed with one-way ANOVA on ranks
followed by Dunn’s test in case of failed normality or variance. Otherwise, one-way ANOVA followed by Student–Newman–Keuls test was used.
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cases also showed recurrent stress-induced AT, which sometimes
triggered VT. In contrast, no atrial arrhythmia was documented in
the Sudanese family. This may be due to the shorter follow-up
related to the high lethality of the disease, as well as differences in
monitoring (the French Canadian patients have a dual-chamber
ICDs, with continuous monitoring of the atrial ECG). The heart was
structurally normal in all affected individuals, with the exception of
two individuals in the Sudanese family that also had tetralogy of
Fallot. Whether these congenital heart defects are part of the same
syndrome or are caused by another genetic defect in this consan-
guineous family remains unclear. During longer follow-up of the
French Canadian cases, it was noted that less potent beta-blockers
A
C
B
Figure 6. AP characteristics of TECRL-hiPSC-CMs.
A AP illustrating the analyzed parameters.
B Representative APs from control (CTRL), heterozygous (HET), and homozygous (HOM) CMs.
C RMP, dV/dtmax, APAmax, APAplat, APD20, APD50, and APD90 of CTRL-, TECRLHet-, and TECRLHom-hiPSC-CMs.
Data information: n = 3–4 cells each from three independent experiments (mean  SEM); *P < 0.05, statistical significance was assessed with one-way ANOVA on ranks
followed by Dunn’s test in case of failed normality or variance. Otherwise, one-way ANOVA followed by Student–Newman–Keuls test was used. AP = action potential;
APAmax = maximum AP amplitude, APAplat = AP plateau amplitude; APD20, APD50, and APD90 = AP duration at 20, 50, and 90% repolarization, respectively; dV/dtmax =
maximum upstroke velocity; RMP = resting membrane potential.
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(metoprolol and bisoprolol) are associated with arrhythmia recur-
rence, while maximal tolerated doses of nadolol were highly
effective.
Whether the clinical phenotype should be classified as LQTS
or CPVT is a subject of discussion. Despite having nearly identi-
cal phenotypes, the Sudanese family was diagnosed with CPVT,
while the French Canadian cases were diagnosed with LQTS. The
arrhythmias were induced by catecholaminergic stimulation, and
most affected individuals had a normal baseline QTc, which
together suggest CPVT. In contrast, mild QTc prolongation in
some patients and the paradoxical QT prolongation during cate-
cholaminergic stimulation indicate a LQTS phenotype (Obeyesek-
ere et al, 2011). Such an overlapping clinical phenotype is also
observed in calmodulin-related inherited arrhythmia (Makita et al,
2014), as well as in KCNJ2 mutations causing Andersen-Tawil
syndrome, which can present as LQTS or CPVT phenocopies
(Kimura et al, 2012). Therefore, we recommend that a
homozygous mutation in TECRL should be considered as a possi-
ble cause of the etiology in patients presenting with stress-
induced complex ventricular arrhythmias or cardiac arrest at a
young age, whether they are diagnosed with (gene-elusive) LQTS
or CPVT. The identification of additional families with the same
syndrome and genetic defect could help in better characterizing/
categorizing the phenotype.
Using murine and human tissues as well as cell lines, we showed
that TECRL expression is restricted to cardiac and skeletal muscles
and that most of the TECRL protein is localized to the ER, which is a
critical site of protein, lipid, and glucose metabolism as well as
calcium homeostasis. Accordingly, reactome pathway analysis indi-
cates a role for TECRL in fatty acid and lipid metabolism while gene
ontology annotates its function as an enzyme involved in catalysis of
redox reactions. In the adult heart, free fatty acids are the primary
substrate for energy production at rest and abnormalities in fatty acid
oxidation have been linked to arrhythmias (Bonnet et al, 1999).
A B
C D
Figure 7. TECRLHom-hiPSC-CMs demonstrate increased susceptibility to triggered activity in response to NA.
A, B Representative AP traces (A) and averaged activity (B) of triggered and spontaneous activity in hiPSC-CMs in the absence of NA.
C, D Representative AP traces (C) and averaged activity (D) of triggered and spontaneous activity in hiPSC-CMs in the presence of NA.
Data information: n = 3–4 cells each from three independent experiments (mean  SEM); *P < 0.05, statistical significance within a group before and after application
of NA was assessed with paired t-test or Wilcoxon signed rank test in case of failed normality; arrows in (A) and (C) indicate last stimulated AP. NA = noradrenaline.
EMBO Molecular Medicine Vol 8 | No 12 | 2016 ª 2016 The Authors
EMBO Molecular Medicine Mutations in TECRL cause lethal arrhythmias Harsha D Devalla et al
1402
Published online: October 24, 2016 
AB
C
D
Figure 8.
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 12 | 2016
Harsha D Devalla et al Mutations in TECRL cause lethal arrhythmias EMBO Molecular Medicine
1403
Published online: October 24, 2016 
Perturbations in physiological levels of lipids/fatty acids and meta-
bolic function can have direct consequences on ion channels and
calcium-handling proteins (Charnock, 1994; Boland & Drzewiecki,
2008; Barth & Tomaselli, 2009). Further studies are necessary to
elucidate the role of TECRL in lipid metabolism and how mutations
are linked to cardiac arrhythmias.
hiPSCs offer important opportunities to model cardiac diseases
in vitro and are especially valuable when myocardial tissue of the
patient is not accessible to determine the consequences of a particu-
lar mutation. Using hiPSC-CMs, we demonstrated that the TECRL
mRNA in TECRLHom-hiPSC-CMs lacks exon 3 and that these cells
recapitulate salient features of the disease phenotype.
Altered calcium homeostasis is a hallmark of CPVT phenotype,
and mutations in RYR2 or CASQ2 have been identified to cause this
disease. Interestingly, protein levels of RYR2 and CASQ2 were signif-
icantly downregulated in TECRLHom-hiPSC-CMs. We also found a
smaller [Ca2+]i transient amplitude in these CMs. Since the Ca
2+
concentration in the SR is a major regulator of the [Ca2+]i transient
amplitude, this finding suggests a lower SR Ca2+ content in
TECRLHom-hiPSC-CMs. Indeed, caffeine-evoked transients in the
presence of 10 mM NiCl2, which are an indicator of SR Ca
2+
content, were significantly lower in TECRLHom-hiPSC-CMs, which
could be associated with downregulation of RYR2.
Additionally, the diastolic [Ca2+]i concentration was significantly
higher in TECRLHom-hiPSC-CMs than in CTRL-hiPSC-CMs, which
could explain their increased propensity to DADs upon adrenergic
stimulation with NA. The increase in diastolic [Ca2+]i in TECRLHom-
hiPSC-CMs may in part be reasoned by the observed decrease in
SERCA and NCX activity. Although we did not observe a decrease in
protein levels of SERCA2A and NCX in TECRLHom-hiPSC-CMs
compared with CTRL-hiPSC-CMs, we noted a decrease in their activ-
ity by functional studies. It has been established that a number of
post-translational modifications regulate the activity of ionophoric
proteins, which could clarify the observed effects (Ruknudin et al,
2007; Stammers et al, 2015). Decreased NCX activity has been
shown to reduce DAD amplitude resulting in fewer spontaneous
APs (Bo¨geholz et al, 2015). However, in our model, despite a lower
NCX activity in TECRLHom-hiPSC-CMs compared with CTRL-hiPSC-
CMs, the increased diastolic [Ca2+]i was sufficient to induce DADs
and subsequent triggered APs.
We also assessed the relative contribution of SERCA, NCX, and
the slow mechanisms to [Ca2+]i removal from the cytosol. In
isolated adult ventricular CMs, the decline of the [Ca2+]i transient is
mainly due to reuptake of Ca2+ into the SR by SERCA and extrusion
of Ca2+ via sarcolemmal NCX with a minor contribution of the slow
mechanisms (Bers, 2006; Dibb et al, 2007). Our results correlate
with this existing data suggesting that the Ca2+ transport systems in
hiPSC-CMs are similar to those reported in adult human and animal
CMs (Bers, 2000).
At the single cell level, APs of TECRLHom-hiPSC-CMs showed an
increase in APD20. Although not significant, APD50 and APD90 were
also prolonged, compatible with the borderline QTc prolongation in
some of the Sudanese patients or with repolarization abnormalities
with QT prolongation occasionally seen on the resting ECG of patient
1. Interestingly, hESC-CMs with TECRL knockdown exhibited mark-
edly prolonged APD20, APD50, and APD90. Collectively, these find-
ings are consistent with an overlapping LQTS/CPVT phenotype in
TECRLHom-hiPSC-CMs manifested by APD prolongation (LQTS) as
well as a disturbed calcium handling and increased propensity for
DADs during catecholaminergic stimulation (CPVT).
Finally, we demonstrated that the antiarrhythmic drug flecainide
suppressed the incidence of triggered APs in TECRLHom-hiPSC-CMs.
Flecainide was first classified as a blocker of Na+ current (INa), and
more recently, it has been shown to reduce exercise-induced
arrhythmias in CPVT patients (Watanabe et al, 2009; van der Werf
et al, 2011). In agreement with flecainide’s effect as INa blocker, we
observed a decrease in AP upstroke velocity. We also observed AP
prolongation, as previously reported in isolated human cardiac
tissue (Wang et al, 1990). The precise mechanisms by which fle-
cainide exerts an antiarrhythmic effect is unclear, but has been
proposed to be due to reduced opening of RYR2 channels (Watan-
abe et al, 2009) or INa blockade resulting in decreased excitability
(Liu et al, 2011; Bannister et al, 2015), or a combination of both
(Watanabe et al, 2009). Although not conclusive, our results
suggest that depression of the upstroke velocity of the AP and the
consequential decrease in excitability contributes to the observed
reduction in triggered activity. It is encouraging that flecainide
reduced the incidence of triggered activity in TECRLHom-hiPSC-CMs.
However, some DADs were still observed emphasizing the need for
additional or more effective drugs to prevent their occurrence in
TECRLHom-hiPSC-CMs. Moreover, the IKr blocking and consequen-
tial QT-prolonging effect of flecainide may potentially offset its
beneficial effect on the triggered activity. CMs generated from
patient-specific hiPSCs were valuable to study the functional conse-
quences of the c.331+1G>A mutation in TECRL. The apparent
immature phenotype of hiPSC-CMs (e.g., APD < 200 ms) as
opposed to freshly isolated human adult ventricular CMs evidently
did not preclude their use in disease modeling.
In conclusion, we identified a novel highly lethal autosomal
recessive inherited arrhythmia syndrome caused by homozygous
mutations in TECRL in patients from three different families. Both
clinical data from patients and cellular functional data from hiPSC-
CMs point toward overlapping features of LQTS and CPVT with trig-
gered activity-mediated arrhythmogenesis. Further studies are
needed to elucidate the exact mechanisms underlying the electrical
phenotype and to assess the prevalence of TECRL mutations in
LQTS, CPVT, and cases of unexplained cardiac arrest. hiPSC lines
from more patients or introduction of targeted mutations in healthy
Figure 8. Flecainide alleviates triggered activity in TECRLHom-hiPSC-CMs.
A Representative AP trace of a TECRLHom-hiPSC-CM in the presence of NA alone or NA and flecainide.
B Effect of flecainide on AP parameters of hiPSC-CMs.
C, D Addition of 5 lM of flecainide decreased the susceptibility to triggered activity in hiPSC-CMs. Note that the effect of flecainide on triggered activity of TECRLHet-
and TECRLHom-hiPSC-CMs is more pronounced than its effect on their spontaneous activity.
Data information: n = 1–2 cells each from three independent experiments (mean  SEM); *P < 0.05, statistical significance within a group before and after application
of flecainide was assessed with paired t-test; arrow in (C) indicates last stimulated AP. NA = noradrenaline, Flec = flecainide.
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control lines may be of value in this context. Screening for muta-
tions in TECRL should be considered in selected cases of suspected
autosomal recessive inherited arrhythmia syndromes.
Materials and Methods
Ethics statement
The French Canadian subjects described in this study were
recruited at the Cardiovascular Genetics Center of the Montreal
Heart Institute. Informed consent was obtained for both subjects
according to procedures approved by the Montreal Heart Institute
Ethics Review Board. Signed informed consent was also obtained
from participating patients from the Sudanese family or their guar-
dians, the study adhered to the Declaration of Helsinki, and the
research protocol was approved by the Al Ain Medical District
Human Research Ethics Committee, College of Medicine, United
Arab Emirates (UAE) University. Study on hESCs and hiPSCs was
performed in the Netherlands, and their use was approved by the
Medical Ethics Committee of Leiden University Medical Center
(LUMC).
Clinical data analysis
French Canadian subjects
Clinical data, including the resting ECGs and 24-h Holter recordings,
were collected and evaluated. Clinical data of family members were
evaluated when possible.
Sudanese family
Clinical data of family members (where possible), including baseline
ECGs, exercise ECGs, and 24-h Holter recordings, were collected
and evaluated. Family members who experienced sudden cardiac
death at young age or who demonstrated arrhythmias were consid-
ered affected.
Exome sequencing
Detailed methods are provided in the Appendix.
French Canadian subjects
Genomic DNA from both patients was extracted from peripheral
blood. A single family member, the father of patient 2, was available
for follow-up genetic testing and was found to be heterozygous for
the Arg196Gln mutation in TECRL.
Sudanese family
Genomic DNA from individuals III:1, III:2, IV:2, and IV:10 (Fig 1D)
was extracted from peripheral blood lymphocytes, and WES was
carried out at the Beijing Genomics Institute (BGI; Shenzhen,
China).
Reprogramming of primary fibroblasts to induced pluripotent
stem cells
Primary fibroblasts from members of the affected family were
isolated from skin biopsies with informed consent under protocols
approved by the Al Ain Hospital Ethics Committee for Research,
SEHA, Abu Dhabi, UAE. Low-passage skin fibroblasts were repro-
grammed to induced pluripotent stem cells using non-integrating
Sendai virus vectors encoding OCT4, SOX2, KLF4, and MYC as
described previously (Zhang et al, 2014). Official identification of
the cell lines used in this study is as follows: LUMC0046iTECRL
(hiPSCs with heterozygous TECRLc.331+1G>A mutation);
LUMC0047iCTRL (control hiPSCs); and LUMC0048iTECRL (hiPSCs
with homozygous TECRLc.331+1G>A mutation).
Of several hiPSC clones with embryonic stem cell morphology
those showing robust expression of pluripotency markers, OCT-4,
NANOG, SSEA4, and/or TRA-181, as analyzed by flow cytometry or
by immunocytochemistry, were selected for further study. These
hiPSC lines were karyotyped and subjected to a global assessment
of pluripotency by PluriTest (Mu¨ller et al, 2011).
Maintenance of hiPSC lines and differentiation to CMs
hiPSC lines were maintained in a feeder-free culture in mTESR1
medium (STEMCELL Technologies) on Matrigel (BD Biosciences) and
passaged once a week with 1 mg/ml dispase (Gibco).
To induce cardiac differentiation, cells were seeded in a high
density on Matrigel and supplemented with mTESR1 medium. Two
days post-seeding, mTESR1 medium was replaced with BPEL
medium (Ng et al, 2008) containing 20 ng/ml activin-A (R&D
systems), 20 ng/ml BMP4 (R&D systems), and 1.5 lmol/l
CHIR99021 (Axon Medchem). On day 3, the medium was replaced
with BPEL medium containing 5 lmol/l XAV939 (Tocris Bios-
ciences). Cells received BPEL medium on day 7 and every 3–4 days
thereafter. Beating CMs were first seen in culture at day 10.
AP measurements
hiPSC-CMs were dissociated to single cells at day 20 using TrypLETM
Select (Life Technologies) and plated on Matrigel-coated coverslips.
APs were recorded 10 days after dissociation with the amphotericin-
perforated patch-clamp technique as described previously (Devalla
et al, 2015) and further detailed in the Appendix.
Ca2+ measurements
hiPSC-CMs were dissociated at day 20, and [Ca2+]i transients were
measured 10 days after dissociation in Indo-1 AM (Molecular
Probes, Eugene, OR, USA) loaded cells as described before (van
Borren et al, 2010; Verkerk et al, 2015) and elaborated in the
Appendix.
Statistics
Experiments with hiPSC-CMs were performed on cells obtained
from n ≥ 3 independent differentiations. Statistical analysis was
carried out with SigmaStat 3.5 software, and data are presented as
mean  standard error of the mean. Normality and equal variance
assumptions were tested with the Kolmogorov–Smirnov and the
Levene median test, respectively. Groups were compared using one-
way analysis of variance (ANOVA) followed by pairwise compar-
ison using the Student–Newman–Keuls test or, in cases of failed
normality and/or equal variance test, ANOVA based on ranks
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(Kruskal–Wallis test) followed by Dunn’s test. P < 0.05 was consid-
ered statistically significant.
Expanded View for this article is available online.
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